SLDB
Solid Biosciences Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-26/100
Last price
6.97
▼ 0.09 (1.27%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
8.00
Prev close
7.06
Day high
7.11
Day low
6.66
Volume
1.19M
Market cap
$742.00M
P/E (TTM)
—
52W range
3.79 – 11.45
Day trading desk
Gap from prior close
+13.31%
Prior close 7.06
VWAP
6.90
+0.96% from price
Relative volume
1.96×
Unusually busy
Session range
20.12%
6.66 – 8.00
Position in range
23%
Near session low
ATR (14D)
0.45
6.53% of price
Prior day high
7.20
PDH
Prior day low
6.77
PDL
Bid / ask spread
—
Quote not published
Session volume
2.15M
Avg 1.10M
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-3.35%
-5.3%
1M
-32.49%
-33.6%
3M
-37.09%
-41.6%
6M
-10.59%
-28.8%
YTD
+22.70%
+8.4%
1Y
+17.29%
+0.9%
3Y
+174.60%
+92.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SLDB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
724.84K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 2, 26 | SMITH IAN F Director |
— | 3.44K | — | Direct |
| Apr 2, 26 | SMITH IAN F Director |
— | 3.44K | — | Direct |
| Feb 18, 26 | HOWTON DAVID TYRONNE Chief Operating Officer |
SELL | 7.47K | $43.49K | Direct |
| Feb 18, 26 | CUMBO ALEXANDER Chief Executive Officer |
SELL | 16.64K | $96.92K | Direct |
| Feb 18, 26 | GANOT ILAN Director |
SELL | 2.66K | $15.48K | Indirect |
| Feb 18, 26 | TAN KEVIN Chief Financial Officer |
SELL | 5.40K | $31.47K | Direct |
| Feb 18, 26 | HANRAHAN JESSIE Officer |
SELL | 4.13K | $24.07K | Direct |
| Feb 18, 26 | HERZICH PAUL Chief Technology Officer |
SELL | 3.62K | $21.06K | Direct |
| Feb 18, 26 | BROOKS GABRIEL M.D. Officer |
SELL | 89.47K | $529.64K | Direct |
| Feb 13, 26 | HOWTON DAVID TYRONNE Chief Operating Officer |
— | 14.69K | — | Direct |
| Feb 13, 26 | CUMBO ALEXANDER Chief Executive Officer |
— | 30.03K | — | Direct |
| Feb 13, 26 | GANOT ILAN Director |
— | 4.86K | — | Indirect |
| Feb 13, 26 | TAN KEVIN Chief Financial Officer |
— | 10.63K | — | Direct |
| Feb 13, 26 | HANRAHAN JESSIE Officer |
— | 8.13K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
ADAGE CAPITAL MANAGEMENT, L.P. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BAIN CAPITAL LIFE SCIENCES INVESTORS, L.L.C. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
BROOKS GABRIEL M.D. |
Officer | 89.47K | Sale |
CUMBO ALEXANDER |
Chief Executive Officer | 235.41K | Sale |
GANOT ILAN |
Director | — | Sale |
HANRAHAN JESSIE |
Officer | 74.32K | Sale |
HOWTON DAVID TYRONNE |
Chief Operating Officer | 105.08K | Sale |
PERCEPTIVE ADVISORS, L.L.C. |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
SMITH IAN F |
Director | 138.15K | Conversion of Exercise of derivative security |
TAN KEVIN |
Chief Financial Officer | 99.42K | Sale |
Fundamentals
Market cap$742.00M
Enterprise value$384.48M
Revenue (TTM)—
Gross profit—
EBITDA$-210.52M
Net income$-207.10M
EPS (TTM)$-1.89
Free cash flow$-118.24M
Total cash$377.68M
Total debt$20.16M
Book value / share$3.56
Shares outstanding107.23M
Float64.81M
Short % of float18.13%
Dividend yield0.00%
Beta (5Y)2.47
Valuation & profitability ratios
Trailing P/E—
Forward P/E-4.06
PEG ratio—
Price / sales—
Price / book1.94
EV / revenue—
EV / EBITDA-1.83
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-65.50%
Return on assets-36.38%
Debt / equity5.39
Current ratio13.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $8.09M | — |
| Operating revenue | $0 | $0 | $0 | $8.09M | — |
| Research & development | $140.32M | $96.43M | $76.56M | $78.42M | +45.5% |
| Selling, general & admin | $38.88M | $33.30M | $27.75M | $28.95M | +16.8% |
| Total operating expense | $179.21M | $129.73M | $104.31M | $107.37M | +38.1% |
| Operating income | -$179.21M | -$129.73M | -$104.31M | -$99.27M | -38.1% |
| Net interest income | $10.11M | $9.13M | $7.14M | $2.62M | +10.7% |
| Pre-tax income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -39.8% |
| Net income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -39.8% |
| Net income to common | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -39.8% |
| Basic EPS | -1.99 | -3.06 | -4.83 | -10.10 | +35.0% |
| Diluted EPS | -1.99 | -3.06 | -4.83 | -10.10 | +35.0% |
| EBIT | -$179.21M | -$124.36M | -$95.58M | -$99.27M | -44.1% |
| EBITDA | -$177.57M | -$121.90M | -$92.99M | -$96.87M | -45.7% |
| Basic shares | 87.50M | 40.82M | 19.88M | 8.51M | +114.4% |
| Diluted shares | 87.50M | 40.82M | 19.88M | 8.51M | +114.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $59.90M | $80.23M | $74.02M | $155.38M | — | -25.3% |
| Cash & short-term investments | $187.85M | $148.92M | $123.64M | $213.72M | — | +26.1% |
| Accounts receivable | — | — | — | $0 | $110.00K | — |
| Total current assets | $205.46M | $157.30M | $129.73M | $219.64M | — | +30.6% |
| Property, plant & equipment | $26.09M | $29.04M | $33.16M | $38.61M | — | -10.2% |
| Total assets | $232.54M | $188.66M | $164.94M | $260.25M | — | +23.3% |
| Total current liabilities | $33.47M | $30.26M | $14.52M | $22.51M | — | +10.6% |
| Total debt | $21.16M | $24.18M | $26.27M | $28.55M | — | -12.5% |
| Total liabilities | $52.53M | $51.42M | $38.46M | $48.59M | — | +2.2% |
| Retained earnings | -$957.77M | -$783.45M | -$658.75M | -$562.74M | — | -22.3% |
| Shareholder equity | $180.01M | $137.25M | $126.48M | $211.67M | — | +31.2% |
| Working capital | $171.98M | $127.05M | $115.22M | $197.13M | — | +35.4% |
| Net tangible assets | $180.01M | $137.25M | $126.48M | $211.67M | — | +31.2% |
| Shares issued | 78.97M | 40.47M | 20.39M | 19.56M | — | +95.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$174.32M | -$124.70M | -$96.02M | -$85.98M | -39.8% |
| Depreciation & amortisation | $1.64M | $2.46M | $2.58M | $2.41M | -33.4% |
| Stock-based compensation | $16.91M | $10.52M | $7.63M | $7.54M | +60.8% |
| Change in working capital | -$6.82M | $2.85M | -$8.87M | -$3.69M | -339.4% |
| Operating cash flow | -$156.29M | -$100.01M | -$94.18M | -$97.98M | -56.3% |
| Capital expenditure | -$1.15M | -$654.00K | -$1.51M | -$3.02M | -76.3% |
| Investing cash flow | -$58.45M | -$16.09M | $9.69M | $59.16M | -263.4% |
| Share buybacks | -$1.68M | -$5.11M | $0 | — | +67.1% |
| Financing cash flow | $194.45M | $122.44M | $3.12M | $74.83M | +58.8% |
| Free cash flow | -$157.44M | -$100.67M | -$95.69M | -$100.99M | -56.4% |
| End cash position | $61.89M | $82.19M | $75.85M | $157.22M | -24.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $44.27M | $46.14M | $38.13M | $38.86M | $32.41M | — | -4.1% |
| Selling, general & admin | $13.12M | $11.17M | $11.27M | $9.20M | $9.28M | — | +17.5% |
| Total operating expense | $57.38M | $57.31M | $49.40M | $48.06M | $41.69M | — | +0.1% |
| Operating income | -$57.38M | -$57.31M | -$49.40M | -$48.06M | -$41.69M | — | -0.1% |
| Net interest income | $3.22M | $2.06M | $2.05M | $2.92M | $2.91M | — | +56.1% |
| Pre-tax income | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | — | +3.4% |
| Net income | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | — | +3.4% |
| Net income to common | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | — | +3.4% |
| Basic EPS | -0.38 | -0.52 | — | -0.48 | -0.42 | -0.59 | +26.9% |
| Diluted EPS | -0.38 | -0.52 | — | -0.48 | -0.42 | -0.59 | +26.9% |
| EBIT | -$54.80M | -$56.74M | -$49.40M | -$48.06M | -$39.42M | — | +3.4% |
| EBITDA | -$54.41M | -$56.34M | -$48.94M | -$47.68M | -$39.03M | — | +3.4% |
| Basic shares | 143.69M | 109.81M | — | 94.42M | 94.14M | 66.34M | +30.9% |
| Diluted shares | 143.69M | 109.81M | — | 94.42M | 94.14M | 66.34M | +30.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $159.39M | $297.10M | $59.90M | $61.36M | $138.93M | -46.3% |
| Cash & short-term investments | $377.68M | $380.68M | $187.85M | $236.14M | $268.11M | -0.8% |
| Total current assets | $395.11M | $396.79M | $205.46M | $244.85M | $278.64M | -0.4% |
| Property, plant & equipment | $24.63M | $25.21M | $26.09M | $26.89M | $27.45M | -2.3% |
| Total assets | $420.58M | $422.89M | $232.54M | $273.91M | $308.29M | -0.5% |
| Total current liabilities | $28.58M | $30.28M | $33.47M | $36.34M | $29.85M | -5.6% |
| Total debt | $20.16M | $20.67M | $21.16M | $21.94M | $23.05M | -2.5% |
| Total liabilities | $46.51M | $48.76M | $52.53M | $55.97M | $50.00M | -4.6% |
| Retained earnings | -$1.07B | -$1.01B | -$957.77M | -$907.99M | -$862.21M | -5.4% |
| Shareholder equity | $374.07M | $374.13M | $180.01M | $217.95M | $258.29M | -0.0% |
| Working capital | $366.52M | $366.50M | $171.98M | $208.51M | $248.79M | +0.0% |
| Net tangible assets | $374.07M | $374.13M | $180.01M | $217.95M | $258.29M | -0.0% |
| Shares issued | 105.13M | 98.39M | 78.97M | 77.88M | 77.60M | +6.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$54.80M | -$56.74M | -$49.79M | -$45.78M | -$39.48M | +3.4% |
| Depreciation & amortisation | $391.00K | $395.00K | $467.00K | $376.00K | $386.00K | -1.0% |
| Stock-based compensation | $5.62M | $5.15M | $6.50M | $3.93M | $3.15M | +9.0% |
| Change in working capital | -$3.94M | $2.31M | -$13.25M | $7.17M | -$2.54M | -270.8% |
| Operating cash flow | -$52.59M | -$47.23M | -$53.55M | -$33.47M | -$37.41M | -11.3% |
| Capital expenditure | -$150.00K | -$165.00K | -$565.00K | -$85.00K | -$377.00K | +9.1% |
| Investing cash flow | -$133.59M | $44.76M | $47.01M | -$45.27M | -$32.73M | -398.5% |
| Share buybacks | -$754.00K | -$12.89M | $0 | $0 | -$1.66M | +94.2% |
| Financing cash flow | $48.47M | $239.03M | $5.14M | $1.18M | -$1.60M | -79.7% |
| Free cash flow | -$52.74M | -$47.40M | -$54.12M | -$33.56M | -$37.79M | -11.3% |
| End cash position | $160.74M | $298.44M | $61.89M | $63.29M | $140.86M | -46.1% |
Options analytics
Put / call volume
3.04
Put-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
7.00
+1.2% from spot
ATM implied vol
3.1%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
24
Contracts, this expiry
Put volume
73
Contracts, this expiry
Heaviest call OI
7.00
0 contracts
Heaviest put OI
7.00
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.47 | -0.38 | +18.9% |
| Mar 2026 | -0.44 | — | — |
| Dec 2025 | -0.52 | -0.53 | -1.8% |
| Sep 2025 | -0.44 | -0.48 | -8.9% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.41 | 13 | $0 | 0.0% |
| Next quarter | -0.43 | 13 | $0 | 0.0% |
| Current year | -1.76 | 13 | $0 | 0.0% |
| Next year | -1.70 | 13 | $8.60M | 0.0% |
Analyst targets & ownership
Mean target$18.62
High target$26.00
Low target$11.00
Implied upside167.08%
Analyst count13
ConsensusSTRONG BUY
Strong buy / Buy5 / 8
Hold0
Sell / Strong sell0 / 0
Held by insiders0.68%
Held by institutions107.41%
Institutions holding215
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
7.23
-3.56% from price
SMA 20
8.03
-13.85% from price
SMA 50
8.72
-20.60% from price
SMA 100
8.45
-17.48% from price
SMA 200
7.60
-9.00% from price
EMA 12
7.47
-6.64% from price
EMA 26
8.08
-13.72% from price
EMA 50
8.42
-17.23% from price
RSI (14)
32.0
Neutral
MACD (12,26,9)
-0.61
Hist -0.12
ATR (14)
0.45
6.57% of price
Realised vol 30D
61.2%
Annualised
Bollinger upper
9.76
20, 2σ
Bollinger lower
6.31
20, 2σ
50 / 200 cross
Golden
8.72 vs 7.60
Trend bias
Below 200
-9.00%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
2.06
More volatile than market
Correlation to SPY
0.34
Loosely linked
Realised vol 30D
61.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-38.6%
Peak to trough
Max drawdown 5Y
-94.9%
Peak to trough
ATR 14
0.45
6.57% of price
Beta (reported)
2.47
5Y monthly, from filing
Short interest
Shares short
17.11M
Prior 16.62M
Change vs prior
+2.9%
Shorts adding
% of float
18.13%
Elevated
% of shares out
15.95%
Against total outstanding
Days to cover
19.5
Crowded exit
Float
64.81M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 16, 26 | RBC Capital | INITIATED | — | Outperform |
| Sep 14, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 27, 26 | Cantor Fitzgerald | MAINTAINED | Overweight | Overweight |
| Aug 21, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Jun 3, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 18, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| May 13, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Mar 25, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| Mar 23, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 26 | Guggenheim | INITIATED | — | Buy |
| Mar 20, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split1:15
Split dateOct 28, 2022
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Corporate Changes & Voting Matters
8-K · 2026-06-10
Periodic Financial Reports
10-Q · 2026-05-12
Proxy Statements
DEFA14A · 2026-04-23
Proxy Statements
PRE 14A · 2026-04-10
A correspondence can be sent as a document with another submission type or can be sent as a separate submission
CORRESP · 2026-03-27
Offering Registrations
S-8 · 2026-03-19
Corporate Changes & Voting Matters
8-K · 2026-03-12
Headlines
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 5d ago
Solid Biosciences' Duchenne Muscular Dystrophy Approach, FDA Shift Support Upside, RBC Says
MT Newswires · 21d ago
RBC Initiates Solid Biosciences at Outperform, Speculative Risk With $18 Price Target
MT Newswires · 21d ago
Solid Biosciences to Participate at Upcoming Investor Conferences
GlobeNewswire · 35d ago
Wedbush Adjusts PT on Solid Biosciences to $15 From $16, Maintains Outperform Rating
MT Newswires · 61d ago
Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 61d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.